AMRXAmneal Pharmaceuticals, Inc.同业对比
Amneal Pharmaceuticals, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMRX本股 | $5.8B#8 | 38.1x#2 | 177.0x#10 | 1.9x#1 | 8.0%#7 | 161.6%#3 | 13.1%#3 | 218.2%#1 | 14.6%#1 | 6#1 | — | — |
| GPCR | $7.5B#1 | — | 5.5x#3 | — | — | -15.2%#10 | — | -10.4%#6 | — | — | — | — |
| RYTM | $6.8B#2 | — | 66.2x#9 | 35.9x#6 | 45.8%#6 | 24.6%#8 | -101.2%#8 | -0.2%#3 | -133.8%#6 | — | — | — |
| ORKA | $6.5B#3 | — | 5.8x#4 | — | — | -25.9%#11 | — | -9.5%#5 | — | — | 489.2%#1 | — |
| MIRM | $6.4B#4 | — | — | 12.3x#3 | 54.7%#5 | 73.4%#5 | -4.2%#4 | — | — | — | — | — |
| LQDA | $6.1B#5 | 48.9x#3 | 31.4x#8 | 38.7x#7 | 1031.2%#1 | 47.1%#7 | -32.5%#7 | -35.3%#10 | — | — | — | — |
| TVTX | $6.1B#6 | — | 248.9x#11 | 12.4x#4 | 110.5%#3 | 92.1%#4 | -12.8%#5 | -104.2%#12 | — | — | — | — |
| GOSS | $5.9B#7 | — | — | 121.2x#8 | -57.7%#9 | -201.4%#15 | -352.2%#9 | — | — | — | -95.1%#3 | — |
| AMRN | — | — | — | — | -6.5%#8 | 55.4%#6 | -23.5%#6 | -8.7%#4 | -16.2%#3 | — | — | — |
| COGT | $5.8B#9 | — | 10.8x#6 | 732.2x#9 | -65.0%#10 | -28.6%#12 | -4235.3%#10 | -61.8%#11 | -84.3%#5 | — | 160.8%#2 | — |
| LGND | $5.7B#10 | 29.4x#1 | 5.9x#5 | 21.2x#5 | 60.4%#4 | 3186.6%#1 | 15.3%#2 | 12.9%#2 | 3.0%#2 | — | — | — |
| PTCT | $5.7B#11 | — | — | 3.3x#2 | 114.5%#2 | 288.0%#2 | 50.1%#1 | — | — | — | — | — |
| DNTH | $5.7B#12 | — | 4.8x#2 | 2780.6x#11 | -67.3%#11 | -91.1%#14 | -8739.3%#12 | -13.9%#7 | — | — | — | — |
| XENE | $5.6B#13 | — | 4.5x#1 | 741.2x#10 | — | -47.6%#13 | -4974.3%#11 | -27.8%#8 | -32.5%#4 | — | — | — |
| ERAS | $5.4B#14 | — | 14.8x#7 | — | — | 23.0%#9 | — | -34.4%#9 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-18。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议